Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to -$170000.0.

  • Inmune Bio's Change in Accured Expenses fell 11299.69% to -$170000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 14467.1%. This contributed to the annual value of -$1.4 million for FY2024, which is 15053.8% down from last year.
  • Per Inmune Bio's latest filing, its Change in Accured Expenses stood at -$170000.0 for Q3 2025, which was down 11299.69% from $473000.0 recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Change in Accured Expenses peaked at $4.2 million during Q4 2023, and registered a low of -$4.1 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $473000.0 (2025), whereas its average is $314894.7.
  • In the last 5 years, Inmune Bio's Change in Accured Expenses tumbled by 228888.89% in 2022 and then soared by 404166.67% in 2025.
  • Inmune Bio's Change in Accured Expenses (Quarter) stood at -$488000.0 in 2021, then skyrocketed by 456.76% to $1.7 million in 2022, then skyrocketed by 142.73% to $4.2 million in 2023, then tumbled by 195.86% to -$4.1 million in 2024, then skyrocketed by 95.8% to -$170000.0 in 2025.
  • Its last three reported values are -$170000.0 in Q3 2025, $473000.0 for Q2 2025, and $659000.0 during Q1 2025.